Get the Stockscreener App
1.43
2.14%
0.03
Boundless Bio Inc stock is traded at $1.43, with a volume of 80,181.
It is up +2.14% in the last 24 hours and up +0.70% over the past month.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
See More
Previous Close:
$1.40
Open:
$1.41
24h Volume:
80,181
Relative Volume:
0.38
Market Cap:
$32.12M
Revenue:
-
Net Income/Loss:
$-55.99M
P/E Ratio:
-0.5717
EPS:
-2.5013
Net Cash Flow:
$-47.60M
1W Performance:
+2.88%
1M Performance:
+0.70%
6M Performance:
+12.60%
1Y Performance:
+37.50%
1-Day Range:
$1.41
$1.4301
1-Week Range:
$1.395
$1.452
52-Week Range:
$0.9612
$1.68
Boundless Bio Inc Stock (BOLD) Company Profile
Name
Boundless Bio Inc
Sector
Industry
Phone
(858) 766-9912
Address
10955 ALEXANDRIA WAY, SAN DIEGO
Compare BOLD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.43 | 32.12M | 0 | -55.99M | -47.60M | -2.5013 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-13-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-22-24 | Initiated | Guggenheim | Buy |
| Apr-22-24 | Initiated | Leerink Partners | Outperform |
| Apr-22-24 | Initiated | Piper Sandler | Overweight |
View All
Boundless Bio Inc Stock (BOLD) Latest News
Boundless Bio Inc (BOLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Boundless Bio Inc (BOLD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Boundless Bio Inc (BOLD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Boundless Bio elects directors and ratifies auditor at annual meeting - Investing.com UK
Boundless Bio Inc (BOLD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Boundless Bio Inc (BOLD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Boundless Bio Inc (BOLD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Boundless Bio Inc (BOLD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Boundless Bio Shareholders Back Directors and Auditor Appointments - TipRanks
Boundless Bio, Inc. Files 8-K with SEC: Company Details, Stock Info, and Emerging Growth Status Revealed - Minichart
[8-K] Boundless Bio, Inc. Reports Material Event - Stock Titan
BOLD Q1 2026 Earnings: EPS Miss as Clinical‑Stage Biotech Focuses on Pipeline ExecutionEarnings Miss Alert - newsline.com
Boundless Bio (BOLD) director receives grant of 32,000 stock options at $1.40 - Stock Titan
Director Jonathan Lim gets 48,000 Boundless Bio (BOLD) options at $1.40 strike - Stock Titan
[Form 4] Boundless Bio, Inc. Insider Trading Activity - Stock Titan
Boundless Bio director granted 32,000 options | BOLD Insider Trading - Stock Titan
SpaceX Sets $75 Billion IPO Record Ahead of Nasdaq DebutNext Quarter Guidance - newsline.com
BOLD Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineMid-Term Outlook - newsline.com
MTUS Q1 2026 Earnings: EPS Surpasses Estimates by 17.65%Short-Term Outlook - newsline.com
VSNT Q1 2026 Earnings: EPS Surges Past Estimates, Stock Moves HigherProfit Guidance Range - newsline.com
BOLD Q1 2026 Earnings: Wider-Than-Expected Loss in Pre-Revenue Phase; Stock Holds Steady - newsline.com
Boundless Bio Halts Early Cancer Trial, Resetting Expectations for BOLD - TipRanks
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Jack In The Box (JACK) Nears Critical Support After 2.83% DeclineBox Spread - newsline.com
Rallybio finds a new reverse-merger dance partner in Avenzo - FirstWord Pharma
Nio Launches First Flagship EV in Two Years, Shares Surge on ES9 SUV DebutForward EPS Estimate - newsline.com
Boundless Bio Inc. (BOLD) Holds Near Support Amid Modest DeclineDividend ETF - The Legal Advocate
ASBA Q1 2026 Earnings: EPS Beats Estimates, Stock Edges HigherRevenue Per Share - newsline.com
AMZN Q1 2026 Earnings: EPS Misses Estimates by 3.6% as Stock Climbs 0.79%Guidance Downgrade Alert - The Legal Advocate
RenovoRx Inc. (RNXT) Moves Higher by 6.2% as Shares Approach Resistance at $1.04Breadth Thrust - The Legal Advocate
Amazon's AI Strategy Sets It Apart from Big Tech Rivals: Focus on Cloud and EnterpriseRevenue Guidance Update - newsline.com
Amer Sports Q1 2026 Earnings: EPS Beats Estimates by 21.1%, Revenue Not DisclosedEarnings Trend Analysis - newsline.com
OM Q1 2026 Earnings: EPS Misses Estimates as Outset Medical Posts Wider-Than-Expected Loss; Stock Edges Up - newsline.com
BBAI Q1 2026 Earnings: AI Specialist Reports Wider Loss, Revenue Data UnavailableEarnings Revision Upgrade - thelegaladvocate.com
Trump Shielded From IRS Audits as Expanded Settlement Deal Draws ScrutinyNet Income Trends - The Legal Advocate
Spyre Therapeutics (SYRE) Stock: Down -2.00%, Support Test at $70.43 2026-05-15Wave Alternation - newsline.com
ZYXI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
RLYB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TradingKey - TradingKey
Number of shareholders of Boundless Bio, Inc. – NASDAQ:BOLD - TradingView
BOLD: ecDNA-targeted therapies offer a novel approach for hard-to-treat oncogene amplified cancers - TradingView
Boundless Bio Releases Q1 2026 Financial Results - AlphaStreet
Boundless Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Boundless Bio, Inc. 1Q 2026: Net income $(13.6)M, EPS $(0.60) — 10-Q Summary - TradingView
Boundless Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Boundless Bio (NASDAQ: BOLD) trims spend, ends HQ lease, guides cash into 2H 2028 - Stock Titan
Boundless Bio (Nasdaq: BOLD) Q1 2026 results and $92.8M cash runway - Stock Titan
Boundless Bio 1Q Loss/Shr 60c >BOLD - Moomoo
Cancer drug trial keeps enrolling as Boundless Bio says cash lasts to 2028 - Stock Titan
What BoundlessBio (BOLD) is doing that smart investors recognize (Breakout Watch) 2026-05-06Crowd Sentiment Stocks - newser.com
Boundless Bio Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Boundless Bio Inc Stock (BOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):